Evaluation and Workup of Leptomeningeal Disease

  • Sushma Bellamkonda
  • David M. PeereboomEmail author


Leptomeningeal disease (LMD) is a devastating complication of cancer and a challenge to treat. This chapter addresses the evaluation and workup of LMD. Since a timely diagnosis can make a difference in the patient’s function and quality of life, it is imperative to be aware of the clinical presentation and diagnostic evaluation of LMD as it is a disease that can easily be missed. Neuroimaging and cerebrospinal fluid (CSF) analysis are the main diagnostic methods. Neuroimaging is more sensitive, whereas CSF analysis is more specific and together can bridge the gap in the diagnosis of LMD.


Leptomeningeal disease Neoplastic meningitis Leptomeningeal carcinomatosis LMD Lumbar puncture CSF Biomarkers Circulating tumor cells Evaluation 


  1. 1.
    Clarke JL. Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn). 2012;18(2):328–42.Google Scholar
  2. 2.
    Suh JH, Chao ST, Peereboom DP, et al. Metastatic cancer to brain. In Devita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, 10th edition. Eds. DeVita V, Lawrence T, Rosenberg S. Philadelphia, Wolters Kluwer. p. 1832–44. 2015.Google Scholar
  3. 3.
    Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006;5(5):443–52.CrossRefPubMedGoogle Scholar
  4. 4.
    Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25(2):103–19.CrossRefPubMedGoogle Scholar
  5. 5.
    Boyle R, Thomas M, Adams JH. Diffuse involvement of the leptomeninges by tumour—a clinical and pathological study of 63 cases. Postgrad Med J. 1980;56(653):149–58.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Saito R, Kumabe T, Jokura H, et al. Symptomatic spinal dissemination of malignant astrocytoma. J Neurooncol. 2003;61(3):227–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49(4):759–72.CrossRefPubMedGoogle Scholar
  8. 8.
    Kokkoris CP. Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid? Cancer. 1983;51(1):154–60.CrossRefPubMedGoogle Scholar
  9. 9.
    Norris LK, Grossman SA, Olivi A. Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: a potentially preventable complication. J Neurooncol. 1997;32(3):215–23.CrossRefPubMedGoogle Scholar
  10. 10.
    Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol. 1996;53(7):626–32.CrossRefPubMedGoogle Scholar
  11. 11.
    Bomgaars L, Chamberlain MC, Poplack DG, et al. Leptomeningeal metastases. In Cancer in the nervous system, 2nd edition. Ed. Levin VA. New York, Oxford University Press. p. 375–93. 2002.Google Scholar
  12. 12.
    Little JR, Dale AJ, Okazaki H. Meningeal carcinomatosis. Clinical manifestations. Arch Neurol. 1974;30(2):138–43.CrossRefPubMedGoogle Scholar
  13. 13.
    Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol. 1974;30(2):122–37.CrossRefPubMedGoogle Scholar
  14. 14.
    Twijnstra A, Ongerboer de Visser BW, Van Zanten AP. Diagnosis of leptomeningeal metastasis. Clin Neurol Neurosurg. 1987;89(2):79–85.CrossRefPubMedGoogle Scholar
  15. 15.
    Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology. 1994;44(8):1463–9.CrossRefPubMedGoogle Scholar
  16. 16.
    DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol. 1998;38(2–3):245–52.CrossRefPubMedGoogle Scholar
  17. 17.
    Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neurooncology. 2008;10(6):1010–8.Google Scholar
  18. 18.
    Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013;4(Suppl 4):S265–88.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Le Rhun E, Galanis E. Leptomeningeal metastases of solid cancer. Curr Opin Neurol. 2016;29(6):797–805.CrossRefPubMedGoogle Scholar
  20. 20.
    Scott BJ, Oberheim-Bush NA, Kesari S. Leptomeningeal metastasis in breast cancer – a systematic review. Oncotarget. 2016;7(4):3740–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Le Rhun ET, Taillibert S, Chamberlain MC. Neoplastic meningitis due to lung, breast and melanoma metastases. Cancer Control. 2017;24(1):22–32.CrossRefPubMedGoogle Scholar
  22. 22.
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. 2016.
  23. 23.
    Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38(1):51–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Straathof CS, de Bruin HG, Dippel DW, et al. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol. 1999;246(9):810–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology. 1990;40(3 Pt 1):435–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Short RG, Bal S, German JP, et al. Potential of F-18 PET/CT in the detection of leptomeningeal metastasis. Neuroradiol J. 2014;27(6):685–9.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Chamberlain MC. Comparative spine imaging in leptomeningeal metastases. J Neurooncol. 1995;23(3):233–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Kramer ED, Rafto S, Packer RJ, et al. Comparison of myelography with CT follow-up versus gadolinium MRI for subarachnoid metastatic disease in children. Neurology. 1991;41(1):46–50.CrossRefPubMedGoogle Scholar
  29. 29.
    Kleinschmidt-DeMasters BK, Damek DM. The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. J Neurooncol. 2010;96(3):375–84.CrossRefPubMedGoogle Scholar
  30. 30.
    Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer. 1995;75(12):2919–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Grossman SA, Trump DL, Chen DC, et al. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med. 1982;73(5):641–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Chamberlain MC, Corey-Bloom J. Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology. 1991;41(11):1765–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Quijano S, Lopez A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin’s lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009;27(9):1462–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82(4):733–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neurooncology. 2001;3(1):42–5.Google Scholar
  36. 36.
    Rogers LR, Duchesneau PM, Nunez C, et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology. 1992;42(6):1239–41.CrossRefPubMedGoogle Scholar
  37. 37.
    Schold SC, Wasserstrom WR, Fleisher M, et al. Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol. 1980;8(6):597–604.CrossRefPubMedGoogle Scholar
  38. 38.
    Sherwin AL, LeBlanc FE, McCann WP. Altered LDH isoenzymes in brain tumors. Arch Neurol. 1968;18(3):311–5.CrossRefPubMedGoogle Scholar
  39. 39.
    Fleisher M, Wasserstrom WR, Schold SC, et al. Lactic dehydrogenase isoenzymes in the cerebrospinal fluid of patients with systemic cancer. Cancer. 1981;47(11):2654–9.CrossRefPubMedGoogle Scholar
  40. 40.
    van Zanten AP, Twijnstra A, Ongerboer de Visser BW, et al. Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy. J Neurol Neurosurg Psychiatry. 1991;54(2):119–23.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Walbert T, Groves MD. Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment. Future Oncol. 2010;6(2):287–97.CrossRefPubMedGoogle Scholar
  42. 42.
    Le Rhun E, Massin F, Tu Q, et al. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012;12:21.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Le Rhun E, Tu Q, De Carvalho Bittencourt M, et al. Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol. 2013;30(2):538.CrossRefPubMedGoogle Scholar
  44. 44.
    Nayak L, Fleisher M, Gonzalez-Espinoza R, et al. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology. 2013;80(17):1598–605. discussion 603CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Lin X, Fleisher M, Rosenblum M, et al. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro Oncol. 2017;19(9):1248–54.Google Scholar
  46. 46.
    Kraan J, Gratama JW, Haioun C, et al. Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom. 2008;Chapter 6:Unit 6.25.Google Scholar
  47. 47.
    de Jongste AH, Kraan J, van den Broek PD, et al. Use of TransFix cerebrospinal fluid storage tubes prevents cellular loss and enhances flow cytometric detection of malignant hematological cells after 18 hours of storage. Cytometry B Clin Cytom. 2014;86(4):272–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Tennessee Health Science CenterMemphisUSA
  2. 2.Department of Medical Oncology, Taussig Cancer InstituteCleveland ClinicClevelandUSA
  3. 3.Rose Ella Burkhardt Brain Tumor and Neuro-oncology CenterCleveland ClinicClevelandUSA

Personalised recommendations